Topical Lingual Signaling Platform
Gila is pioneering a newly discovered biological pathway, the tongue-brain connection, to develop safer and more effective treatments for obesity and cardiometabolic disorders.
Our Technology
At Gila Therapeutics, we’re developing a first-of-its-kind technology that leverages an unexploited biological pathway to activate targeted areas of the brain directly implicated in regulating food intake and metabolism. Unlike other treatments, the core of our approach is based on signaling via oral receptors to activate specific target areas of the brain responsible for metabolic regulation while avoiding areas responsible for side effects* such as nausea.
Topical Lingual PYY signaling directly targets/activates Nucleus Tractus Solitarius
Micro-dose PYY melts on tongue in less than three seconds
Does not enter bloodstream & no expected side effects*
*No expected side effects, and no side effects seen in extensive toxicology, pre-clinical studies (most notably dogs and Asian musk shrews exhibit zero emesis) and successful Phase I (zero treatment-related adverse events).
Who We Are
Gila Therapeutics is a clinical stage biotech company exploiting a novel, highly-targeted neural signaling system for the treatment of obesity, type 2 diabetes, and associated metabolic disorders. Our scientific advisory team is renowned globally for their unrivaled experience and pioneering contributions to the fields of endocrinology, neuroscience, and metabolic nephrology.
Our Partnerships
Through collaborations with esteemed pharmaceutical, biotech, and consumer health pioneers, as well as distinguished research universities, we have forged strategic alliances to advance our research and fulfill our mission of bringing the world's inaugural Topical Lingual PYY & GLP1 to the market.
